MX352024B - Formulaciones potentes de liberacion controlada. - Google Patents

Formulaciones potentes de liberacion controlada.

Info

Publication number
MX352024B
MX352024B MX2014006625A MX2014006625A MX352024B MX 352024 B MX352024 B MX 352024B MX 2014006625 A MX2014006625 A MX 2014006625A MX 2014006625 A MX2014006625 A MX 2014006625A MX 352024 B MX352024 B MX 352024B
Authority
MX
Mexico
Prior art keywords
low viscosity
compositions
forming
acyl
release formulations
Prior art date
Application number
MX2014006625A
Other languages
English (en)
Other versions
MX2014006625A (es
Inventor
Tiberg Fredrik
Johnsson Markus
Original Assignee
Camurus Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47226199&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX352024(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Camurus Ab filed Critical Camurus Ab
Publication of MX2014006625A publication Critical patent/MX2014006625A/es
Publication of MX352024B publication Critical patent/MX352024B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)

Abstract

La presente invención se relaciona con composiciones que forman una mezcla de baja viscosidad de: a. al menos un diacilglicerol y/o al menos un tecoferol; b. al menos un componente fosfolípido que comprende fosfolípidos que tienen, i. grupos de cabeza polar que comprenden más de un 50% de fosfatidiletanolamina, y ii. Dos cadenas de acilo, cada una tiene independientemente de 16 a 20 carbonos, donde al menos una cadena de acilo tiene al menos una insaturación en la cadena de carbono, y no existen más de cuatro insaturaciones en dos cadenas de carbono; c. al menos un solvente orgánico biocompatible, de baja viscosidad, que contiene oxígeno; donde, opcionalmente, se disuelve o dispersa al menos un agente bioactivo en la mezcla de baja viscosidad; y donde la predormulación forma, o tiene la capacidad de formar, al menos una estructura de fase cristalina líquida no laminar al contacto con un fluido acuoso. La invención se relaciona adicionalmente con métodos de tratamiento que comprenden la administración de tales composiciones y con dispositivos de administración precargados y kits que contienen las formulaciones.
MX2014006625A 2011-12-05 2012-11-28 Formulaciones potentes de liberacion controlada. MX352024B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161566851P 2011-12-05 2011-12-05
PCT/EP2012/073843 WO2013083460A1 (en) 2011-12-05 2012-11-28 Robust controlled-release formulations

Publications (2)

Publication Number Publication Date
MX2014006625A MX2014006625A (es) 2014-09-22
MX352024B true MX352024B (es) 2017-11-07

Family

ID=47226199

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014006625A MX352024B (es) 2011-12-05 2012-11-28 Formulaciones potentes de liberacion controlada.
MX2014006624A MX350929B (es) 2011-12-05 2012-11-28 Formulaciones peptidicas robustas de liberación controlada.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2014006624A MX350929B (es) 2011-12-05 2012-11-28 Formulaciones peptidicas robustas de liberación controlada.

Country Status (23)

Country Link
US (2) US9585959B2 (es)
EP (2) EP2787975B1 (es)
JP (2) JP6081479B2 (es)
KR (2) KR20140105527A (es)
CN (2) CN104105479B (es)
AU (2) AU2012348641B2 (es)
BR (2) BR112014013693B1 (es)
CA (2) CA2858227C (es)
CL (1) CL2014001472A1 (es)
CO (1) CO7000746A2 (es)
DK (2) DK2787974T3 (es)
EA (2) EA027924B1 (es)
ES (2) ES2645345T3 (es)
HK (2) HK1201722A1 (es)
HR (1) HRP20170954T1 (es)
IL (2) IL232789B (es)
MX (2) MX352024B (es)
PE (1) PE20141297A1 (es)
PL (1) PL2787975T3 (es)
SG (1) SG11201402673YA (es)
SI (1) SI2787974T1 (es)
WO (2) WO2013083460A1 (es)
ZA (1) ZA201403793B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0511807C8 (pt) * 2004-06-04 2021-05-25 Camurus Ab pré-formulação, processo de formação de uma pré-formulação e uso da mesma
GB0711656D0 (en) * 2007-06-15 2007-07-25 Camurus Ab Formulations
US11433120B2 (en) * 2011-05-25 2022-09-06 Camurus Ab Controlled release peptide formulations
AU2013265210B2 (en) * 2012-05-25 2016-09-15 Camurus Ab Somatostatin receptor agonist formulations
SI2877155T1 (sl) 2012-07-26 2021-04-30 Camurus Ab Opioidne formulacije
EP2823808A1 (en) * 2013-07-09 2015-01-14 Ipsen Pharma S.A.S. Pharmaceutical composition for a sustained release of lanreotide
KR20160075665A (ko) 2013-10-22 2016-06-29 프로린크스 엘엘시 소마토스타틴 및 그 유사체의 컨쥬게이트
WO2016092569A1 (en) * 2014-12-10 2016-06-16 Council Of Scientific & Industrial Research A discontinuous reverse micellar composition in cubic fd3m phase for sustained release of therapeutic drugs
AU2015370922B2 (en) * 2014-12-23 2018-10-04 Camurus Ab Controlled-release formulations
GB201516554D0 (en) * 2015-09-18 2015-11-04 Camurus Ab Controlled-release formulations
ITUB20160416A1 (it) * 2016-01-28 2017-07-28 Italfarmaco Spa Uso di una formulazione a lento rilascio di octreotide per la prevenzione della formazione di seroma
BR112018069591A2 (pt) * 2016-03-31 2019-04-16 Sun Pharma Advanced Research Company Limited gel viscoelástico e método para o controle de níveis de glicose no sangue
KR20190083645A (ko) * 2016-09-15 2019-07-12 카무러스 에이비 프로스타글란딘 유사체 제제
AU2017336199B2 (en) 2016-09-27 2020-08-20 Camurus Ab Mixtures and formulations comprising an alkyl ammonium EDTA salt
US10779576B2 (en) 2017-05-24 2020-09-22 VMR Products, LLC Flavor disk
WO2019182745A1 (en) 2018-03-19 2019-09-26 Bryn Pharma, LLC Epinephrine spray formulations
JP2021523223A (ja) 2018-05-01 2021-09-02 チビ，インコーポレイティド 眼への薬物の非侵襲的な持続型送達のための液体デポー
AU2019262061A1 (en) * 2018-05-01 2020-11-26 Chibi, Inc. Eye drop formulation and method for sustained delivery of medicament to the retina
CN108498849B (zh) * 2018-05-08 2021-04-30 武汉百纳礼康生物制药有限公司 一种液晶凝胶肝动脉栓塞剂及其制备方法
CN109091451B (zh) * 2018-09-10 2021-08-13 武汉百纳礼康生物制药有限公司 亲水性药物的油相液晶凝胶前体制剂及其制备方法
EA202192919A1 (ru) 2019-05-29 2022-02-18 Камурус Аб Композиции на основе липидов с контролируемым высвобождением
WO2021160887A1 (en) 2020-02-14 2021-08-19 Immunor As Corona virus vaccine
JP7542661B2 (ja) * 2020-06-30 2024-08-30 チョン クン ダン ファーマシューティカル コーポレーション Ｇｎｒｈ誘導体を含む注射用組成物
US20230372317A1 (en) * 2020-10-27 2023-11-23 Pts Consulting, Llc A liquid injectable composition of donepezil
CN113081954A (zh) * 2021-05-25 2021-07-09 南昌大学第二附属医院 一种凝胶载药贴剂药物输送系统
CN117794519A (zh) * 2021-07-27 2024-03-29 法纳克斯株式会社 非层状液晶形成性组合物及其用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8206744D0 (sv) 1982-11-26 1982-11-26 Fluidcarbon International Ab Preparat for kontrollerad avgivning av substanser
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5538739A (en) 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
WO1995026715A2 (en) * 1994-03-30 1995-10-12 Dumex-Alpharma A/S Use of fatty acid esters as bioadhesive substances
SE518578C2 (sv) 1994-06-15 2002-10-29 Gs Dev Ab Lipidbaserad komposition
PT839525E (pt) 1996-10-31 2004-10-29 Takeda Chemical Industries Ltd Preparacao de libertacao prolongada
BE1011899A6 (fr) * 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
JP3952617B2 (ja) 1998-12-11 2007-08-01 株式会社日立製作所 内燃機関の排ガス浄化装置，排ガス浄化方法及び排ガス浄化触媒
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
US20080112915A1 (en) 2003-10-24 2008-05-15 Marianna Foldvari Dna Delivery with Gemini Cationic Surfactants
WO2005046642A1 (en) 2003-11-07 2005-05-26 Camurus Ab Compositions of lipids and cationic peptides
GB0401513D0 (en) 2004-01-23 2004-02-25 Camurus Ab Compositions
DE602005025083D1 (es) 2004-01-23 2011-01-13 Camurus Ab
BRPI0511807C8 (pt) 2004-06-04 2021-05-25 Camurus Ab pré-formulação, processo de formação de uma pré-formulação e uso da mesma
WO2006002050A1 (en) * 2004-06-15 2006-01-05 Encore Therapeutics, Inc. Phospholipid compositions and methods for their preparation and use
CA2594718C (en) 2005-01-14 2012-01-24 Camurus Ab Gnrh analogue formulations
EP1843746B1 (en) 2005-01-14 2011-03-16 Camurus Ab Somatostatin analogue formulations
US9060935B2 (en) 2005-01-21 2015-06-23 Camurus Ab Pharmaceutical lipid compositions
JP5198261B2 (ja) 2005-06-06 2013-05-15 カムルス エービー Ｇｌｐ−１類似体製剤
GB0711656D0 (en) 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0716385D0 (en) * 2007-08-22 2007-10-03 Camurus Ab Formulations

Also Published As

Publication number Publication date
IL232789B (en) 2019-11-28
US9555118B2 (en) 2017-01-31
EP2787975A1 (en) 2014-10-15
DK2787975T3 (da) 2017-11-20
JP2015505833A (ja) 2015-02-26
AU2012348641A1 (en) 2014-06-19
SG11201402673YA (en) 2014-06-27
EA201490921A1 (ru) 2014-11-28
PL2787975T3 (pl) 2018-01-31
EP2787975B1 (en) 2017-10-04
PE20141297A1 (es) 2014-10-09
MX2014006624A (es) 2014-09-22
BR112014013693B1 (pt) 2023-01-31
US20140348903A1 (en) 2014-11-27
IL232967A0 (en) 2014-07-31
CL2014001472A1 (es) 2014-11-21
CO7000746A2 (es) 2014-07-21
IL232789A0 (en) 2014-07-31
KR101979051B1 (ko) 2019-05-15
BR112014013691A2 (pt) 2017-06-13
CN104093399B (zh) 2018-03-13
MX2014006625A (es) 2014-09-22
EA201491005A1 (ru) 2014-11-28
EP2787974B1 (en) 2017-05-24
CA2858227A1 (en) 2013-06-13
AU2012348640A1 (en) 2014-07-17
CN104105479A (zh) 2014-10-15
HK1201735A1 (en) 2015-09-11
MX350929B (es) 2017-09-26
EA027924B1 (ru) 2017-09-29
HK1201722A1 (en) 2015-09-11
KR20140105527A (ko) 2014-09-01
CN104093399A (zh) 2014-10-08
ES2645345T3 (es) 2017-12-05
DK2787974T3 (en) 2017-07-17
US20140329749A1 (en) 2014-11-06
US9585959B2 (en) 2017-03-07
WO2013083459A1 (en) 2013-06-13
WO2013083460A1 (en) 2013-06-13
AU2012348641B2 (en) 2016-04-21
CA2857982A1 (en) 2013-06-13
ES2629188T3 (es) 2017-08-07
EA028040B1 (ru) 2017-09-29
KR20140111661A (ko) 2014-09-19
HRP20170954T1 (hr) 2017-09-22
SI2787974T1 (sl) 2017-10-30
BR112014013693A2 (pt) 2020-06-30
JP6081480B2 (ja) 2017-02-15
ZA201403793B (en) 2017-04-26
CN104105479B (zh) 2018-04-10
EP2787974A1 (en) 2014-10-15
JP2015500253A (ja) 2015-01-05
JP6081479B2 (ja) 2017-02-15
AU2012348640B2 (en) 2016-07-21
CA2858227C (en) 2021-01-05

Similar Documents

Publication Publication Date Title
MX352024B (es) Formulaciones potentes de liberacion controlada.
MX2013013401A (es) Formulaciones pepticidas de liberacion controlada.
ECSP14012527A (es) Composiciones enriquecidas con dpa de ácidos grasos omega 3 poliinsaturados en forma de ácido libre
DOP2013000105A (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogénesis
ATE401054T1 (de) Flüssige depotformulierungen
PE20130230A1 (es) Derivados de carboxamidas n-azabiciclicas y su preparacion
MX2018003333A (es) Formulaciones de liberacion controlada.
EA201490489A1 (ru) Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
MY156858A (en) Low-oil pharmaceutical emulsion compositions comprising progestogen
CR20130210A (es) DERIVADOS DE IMIDAZO[1,2-b]PIRIDAZINA E IMIDAZO[4,5-B]PIRIDINA COMO INHIBIDORES DE JAK
ATE501710T1 (de) Somatostatin-analog-formulierungen
CL2011000144A1 (es) Compuestos derivados de benzo (1,4) dioxin-2-ilmetil-sulfamida; composiciones farmaceuticas que los contienen; proceso para prepararlos y uso en el tratamiento de la ansiedad, epilepsia, dolor, abuso de sustancias, trastornos relacionados, entre otros.
IL251413B2 (en) Composition of injectable buprenorphine
RU2014144500A (ru) Депо-составы местного анестетика и способы их получения
BR112012015433B8 (pt) composição farmacêutica substancialmente anidra para aplicação cutânea
HRP20210068T1 (hr) Opioidne formulacije
TN2014000483A1 (en) Somatostatin receptor agonist formulations
MX2019003520A (es) Mezclas y formulacions que comprenden una sal de alquil amonio de acido etilendiaminotetraacetico (edta).
CR11823A (es) Compuestos de pirazina fusionados utiles para el tratamiento de enfermedades degenarativas e inflamatorias
BR112021023549A2 (pt) Composições terapêuticas estáveis em solventes polares apróticos e seus métodos de fabricação
BR112015015476A8 (pt) uso de compostos químicos capazes de inibir a ação tóxica das esfingomielinases d do veneno de aranhas loxosceles e composição farmacêutica compreendendo os referidos compostos
ECSP10010663A (es) Compuestos de pirazina fusionados utiles para el tratamiento de enfermedades degenarativas e inflamatorias
RU2012127261A (ru) Фармацевтическая композиция хондропротекторов для трансдермального применения
AR084411A1 (es) SUSPOEMULSION ACUOSA QUE CONTIENE LUFENURON Y l-CIHALOTRINA Y PROCEDIMIENTO PARA PREPARARLA
TN2012000505A1 (en) Low-oil pharmaceutical emulsion compositions comprising progestogen

Legal Events

Date Code Title Description
FG Grant or registration